RetinoicAcidReceptoralpha抗体;RetinoicAcidReceptoralpha Antibody—艾普蒂

+ +

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

The retinoic acid receptor alpha (RARα) is a member of the nuclear receptor superfamily that mediates the effects of retinoic acid (RA), a metabolite of vitamin A, by regulating gene expression. As a ligand-dependent transcription factor, RARα plays critical roles in embryonic development, cellular differentiation, proliferation, and apoptosis. It forms heterodimers with retinoid X receptors (RXRs) to bind specific DNA response elements, modulating the transcription of target genes involved in cell cycle control, immune function, and tissue homeostasis. Dysregulation of RARα is implicated in various pathologies, including acute promyelocytic leukemia (APL), where chromosomal translocations generate oncogenic fusion proteins disrupting normal RA signaling.

Antibodies targeting RARα are essential tools for studying its expression, localization, and function in both physiological and disease contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP) to investigate RARα's role in development, cancer, and metabolic disorders. High-quality RARα antibodies exhibit specificity for distinct epitopes, enabling detection of full-length proteins, isoforms, or post-translational modifications. Their applications extend to diagnostic and therapeutic research, particularly in cancers with RARα aberrations. Validation using knockout models or siRNA knockdown ensures reliability, making these antibodies indispensable for unraveling RA signaling mechanisms and developing targeted therapies.